425, Summer St

Boston,

MA,

USA,

ZIP: 02210

Phone: +16174554188

Over the last 12 months, we have seen many combination therapies enter Phase I and II trials with both successes and challenges, particularly in solid tumors. The FDA Modernization Act 2.0 passing has also steered biopharma away from animal models, empowering the preclinical and translational tumor models' space to continue innovating and decrease the translational gap into the clinic.

At the 11th Annual Tumor Models Boston Summit, you will gain practical insights into the latest updates through 25+ case studies across 2 dedicated tracks. Join us to learn from and meet pioneers in preclinical and translational targeted, combination oncology to advance your candidates to patients with optimized translatability, efficiency, and cost-effectiveness!

URLs:
Tickets: https://go.evvnt.com/1642229-2?pid=1052
Brochure: https://go.evvnt.com/1642229-3?pid=1052

Speakers: Aaron Goldman, Instructor in Medicine, Harvard Medical School, Antje Margret Wenger, Head of Immuno Ocology, Bayer AG, Aundrietta Duncan, Director, Non-Clinical Development, Salarius Pharmaceuticals, Carlos Gil del Alcazar, Lab Head, Novartis, Charles Lin, Senior Vice President, Kronos Bio, Dina Polyak, Senior Scientist II, Arsenal Biosciences, Doug Palmer, Executive Director, Immuno-Oncology Translational Medicine, AstraZeneca, Emmett Schmidt, Vice President, Merck, Francesca Vena, Business Development Director, Imagen Therapeutics, Giovanni Marconi, MD Consultant, Haematolog, IRST, John Maher, Chief Scientific Officer, LeucidBio, Joshua Breunig, Associate Professor, Cedars-Sinai Medical Center, Katie Grausam, Postdoctoral Scientist, Cedars Sinai, Kim Aardalen, Director, Preclinical Pharmacology Oncology, Odyssey Therapeutics, Ludovic Bigot, Project Manager, Gustav Rousey, Marco Campisi, Postdoctoral Research Fellow, Dana-Farber Cancer Institute, Melinda Day, Associate Director Translational Clinical Development, Kronos Bio, Michael Boice, Vice President, Scientific Engagement, TD2 Precision Oncology, Monika Buczek, PhD, Director of Business Development, Business Development, Natalia Malkova, Director, In Vivo Pharmacology, Xilio Therapeutics, Rakesh Awasthi, Senior Principal Scientist, Oncology Clinical Pharmacology, Novartis, Sam Chatterjee, Translational Scientist, Cell Therapy, Takeda, Shanthi Ganesh, Director, Discovery Research Pre-Clinical Oncology, Discerna Pharmaceuticals, Shou-Ching Jaminet, Co-Founder and Vice President of Discovery Science, Anglex, Stephanie Casey Parks, Senior Scientist, Oncology and Inflammation, Amgen, Steve Anderson, Consultant, Precision Medicine and Oncology, Tessa DesRochers, Chief Scientific Officer, Kiyatec Inc, Yongxian Zhuang, Director, Cancer Pharmacology, Revolution Medicines